Trials Sponsors Conditions Drugs Pricing

Conditions

Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Small Cell Carcinoma Cervical Squamous Cell Carcinoma Recurrent Cervical Carcinoma

Outcome Measures

Primary Outcomes (2)

Overall survival
From entry to protocol to death; or for living patients, the date of last contact, up to 93 years
Progression-free survival
From study entry to date of reappearance or increasing parameters of disease or death, or to date of last contact for patients without disease progression, up to 93 years

Secondary Outcomes (1)

Impact of surgery therapy (exenteration and reconstructive surgery type) on quality of life assessed by Functional Assessment of Cancer Therapy-Cervix (FACT-CX)
At baseline, 6, 12, and 24 months post exenteration

Study Arms (1)

Treatment (pelvic exenteration)

EXPERIMENTAL

Patients undergo pelvic exenteration within 14 days after study entry.

Procedure: Conventional Surgery

Interventions

Conventional SurgeryProcedure

Treatment (pelvic exenteration)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Diagnosis of cervical cancer
Any histology

Sponsors & Collaborators

Gynecologic Oncology Group
Research networklead
National Cancer Institute (NCI)
NIHcollaborator

Study Sites (39)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States

Colorado Gynecologic Oncology Group

Aurora, Colorado, 80010, United States

Hartford Hospital

Hartford, Connecticut, 06102, United States

The Hospital of Central Connecticut

New Britain, Connecticut, 06050, United States

Beebe Medical Center

Lewes, Delaware, 19958, United States

Christiana Care Health System-Christiana Hospital

Newark, Delaware, 19718, United States

Georgia Regents University Medical Center

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

D. McMeekin
Gynecologic Oncology Group
PRINCIPAL INVESTIGATOR

Enrollment

38 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: NETWORK
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 20, 2005

First Posted

September 22, 2005

Study Start

January 2006

Date type not reported

This date has not been verified as actual or estimated.

Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (1)

Treatment (pelvic exenteration)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (39)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (1)

Treatment (pelvic exenteration)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (39)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations